Canopy Growth has stabilized its balance sheet and rebuilt around medical cannabis, but profitability, dilution, and accounting-control failures keep the turnaround firmly in “prove it” territory.
On June 15, 2026, Canopy Growth Corporation released its fourth-quarter and full-year fiscal 2026 financial results, revealing a complex operational and financial transformation.[1, 2] This equity research report provides an institutional-grade evaluation of the company's financial health, strategic repositioning, and equity valuation on the day of these releases. Canopy Growth reported fiscal fourth-quarter net revenue of C$71.2 million, representing a 10% year-over-year increase, but missed Wall Street estimates by C$3.31 million.[1, 3] Bottom-line profitability was heavily pressured, with a GAAP loss of C$0.40 per share, significantly missing the consensus analyst estimate of a loss of C$0.1041 per share by 284%.[3] The miss was primarily driven by C$10.7 million in fourth-quarter inventory write-offs and asset impairments associated with the integration of MTL Cannabis.[1, 3]
Despite the bottom-line miss, the operational trajectory indicates significant structural progress. Canopy Growth closed fiscal 2026 with a net cash position of C$131.3 million, marking a C$304 million improvement from the net debt position of C$172.6 million in the prior fiscal year.[1, 4] This recapitalization resolved historical going-concern doubts.[5] Operationally, the company recorded strong momentum in high-margin segments, led by a 27% increase in Canadian medical cannabis net revenue to a record C$25.3 million in the fourth quarter, alongside a 68% increase in international markets cannabis net revenue to C$8.6 million.[1, 3]
However, these operational successes are offset by corporate governance and accounting challenges. Concurrent with the earnings release, the audit committee announced a comprehensive financial restatement for the fiscal years ended March 31, 2024, and March 31, 2025, to correct a non-cash accounting error regarding the classification of U.S.-dollar share-settled warrants.[6, 7] Consequently, management concluded that the company's internal control over financial reporting was not effective as of March 31, 2026.[7] Additionally, the hardware-focused Storz & Bickel segment experienced a 14% annual revenue contraction, and the company took a C$67.1 million impairment charge on its goodwill and brands.[8]
This analysis maintains a neutral "Hold" rating on Canopy Growth Corporation. The company’s improved balance sheet and strong position in the Canadian medical and German medical import markets are positive developments.[1, 9, 10] However, persistent GAAP net losses, accounting complexities, and execution risks in the non-medicinal divisions suggest a cautious approach is warranted.[1, 7]
Canopy Growth's strategic focus is centered on high-margin medical cannabis markets and premium adult-use product lines, representing a significant shift from its historical focus on building high-volume production capacity.[11]
The Canadian medical cannabis division is Canopy Growth's most profitable business segment, achieving record fourth-quarter net revenue of C$25.3 million, up 27% year-over-year.[1, 3] Full-year segment net revenue grew 18% to C$90.8 million, driven by an expanding base of insured patients and a larger premium product assortment offered through the Spectrum Therapeutics platform.[1, 8]
The strategic cornerstone of this division is the completed acquisition of MTL Cannabis, which positioned Canopy Growth as Canada’s leading medical cannabis provider by revenue.[2] The integration of MTL Cannabis has progressed rapidly, with the company already realizing C$6.0 million of its targeted C$10.0 million in annualized cost synergies.[12, 13] Beyond cost reductions, the transaction provides Canopy with consistent high-quality flower, addressing historical supply chain issues and enabling premium product lines to scale.[3, 13]
In the recreational market, Canopy Growth has consolidated its market position, improving its national ranking from eighth to sixth overall by May 2026.[12, 13] Full-year adult-use net revenue increased 20% to C$94.5 million, supported by product introductions in high-growth categories, including infused pre-roll joints (PRJs), vapes, and high-THC flower under the Tweed and Claybourne brands.[3, 8]
However, fourth-quarter adult-use net revenue flattened to C$20.6 million, an increase of only 1% compared to the prior-year period.[1, 8] This slower quarterly growth reflects management's rationalization of low-margin formats and adjustments at its cultivation facilities to align production with high-margin demand.[8, 13] The launch of the premium "Deelish" brand and Claybourne's award-winning "Frosted Flyers" infused pre-rolls highlight the company's shift toward value-added product categories over commoditized flower.[2, 3]
The international cannabis segment generated C$8.6 million in the fourth quarter, representing a 68% year-over-year surge, which offset a 7% decline in full-year international net revenue.[1, 8] The fourth-quarter recovery was driven by the resolution of European supply chain constraints that had restricted sales earlier in the fiscal year.[5, 8]
Germany is the primary driver of international growth, where the declassification of medical cannabis under the Cannabis Act (CanG) in April 2024 has transformed the market.[10, 14] By removing medical cannabis from the narcotics list, the law simplified prescribing procedures for physicians and enabled the expansion of telemedicine platforms.[14] Telemedicine has added an estimated 500,000 to 600,000 self-paying patients to the German market.[14] To capitalize on this, Canopy Growth relaunched its core Tweed brand in Germany, utilizing premium strains from the MTL Cannabis acquisition.[15]
However, the German market is experiencing structural shifts. Total medical cannabis imports grew from 72 tonnes in 2024 to approximately 201 tonnes in 2025, and are projected to reach 250 tonnes in 2026.[10] While total sales doubled from €1.0 billion in 2024 to €2.0 billion in 2025, the number of tracked flower lines rose to over 1,800 by mid-2026, leading to a near 33% decline in the average price per gram.[14, 16] This price compression presents a challenge for importers that cannot maintain premium, differentiated product profiles.[10, 16]
The premium vaporizer division, Storz & Bickel, has faced ongoing operational challenges.[3] Net revenues declined 14% in both the fourth quarter (C$16.8 million) and the full fiscal year (C$70.7 million).[1, 8] This decline is primarily due to weaker consumer discretionary spending in its core U.S. and German markets, alongside difficult comparisons from prior periods that featured major product launches.[8] Tariffs on imports into the United States and geographic mix shifts also compressed segment gross margins to 27% in the fourth quarter and 33% for the full year.[8] In response, Canopy Growth recorded C$67.1 million in asset impairment and restructuring charges, primarily relating to the write-down of goodwill and brands at Storz & Bickel.[8, 17] Management is attempting an operational reset focused on the new VEAZY product line and expanding retail sales channels in the United States.[3, 8]
Canopy Growth’s U.S. strategy is executed through its off-balance-sheet holding vehicle, Canopy USA, LLC.[18, 19] By December 2024, Canopy USA had consolidated its acquisitions of Acreage Holdings, Wana Wellness, and a 77% stake in Lemurian (Jetty).[18, 19] Canopy Growth does not consolidate the financial results of Canopy USA, holding its interest in non-voting exchangeable shares that represent an 84.4% stake on an as-converted basis.[18, 19] This structure allows Canopy Growth to retain significant equity exposure to the U.S. commercial market without violating the listing requirements of major exchanges.[9] While Canopy USA is positioned to benefit from potential federal regulatory changes, such as the DEA's proposed rescheduling to Schedule III, the vehicle is keeping capital expenditures disciplined to preserve cash ahead of formal legislative changes.[3, 9]
Canopy Growth's fiscal year ended March 31, 2026, was marked by significant balance sheet restructuring and cost reductions, offset by ongoing GAAP losses and write-offs.[1]
Consolidated net revenue for fiscal 2026 was C$284.6 million, an increase of 6% compared to the restated C$268.6 million in fiscal 2025.[1, 20] The full-year reported gross margin compressed to 24% from 30% in the prior year, primarily due to C$10.7 million in fourth-quarter inventory write-offs and purchase accounting adjustments tied to the MTL Cannabis transaction.[8] However, excluding these transaction-related charges, the fourth-quarter adjusted gross margin improved to 27% from 19% in the prior-year period, reflecting lower cultivation and manufacturing costs in the Canadian cannabis segment.[8]
Operating expenses improved, driven by headcount reductions, lower insurance costs, and reduced professional fees.[8] Selling, General, and Administrative (SG&A) expenses fell 6% for the full year, while General and Administrative (G&A) operating expenses declined by C$9.5 million, or 15%.[3, 8] This cost control helped narrow the full-year Adjusted EBITDA loss to C$20.2 million from C$23.5 million.[1] Full-year free cash outflow from continuing operations also improved significantly, narrowing to C$69.1 million from C$176.6 million in fiscal 2025.[1]
Figures in Thousands of Canadian Dollars (CAD), except per share data
| Income Statement Line Item | FY2026 | FY2025 (Restated) | YoY Change (%) |
|---|---|---|---|
| Consolidated Net Revenue | C$ 284,600 | C$ 268,600 | 6.0% |
| Cost of Goods Sold (COGS) | C$ 216,296 | C$ 188,020 | 15.0% |
| Gross Profit | C$ 68,304 | C$ 80,580 | (15.2)% |
| Gross Margin (%) | 24.0% | 30.0% | (600 bps) |
| Restructuring & Impairments | C$ 67,100 | C$ 114,800 | (41.6)% |
| Adjusted EBITDA | C$ (20,200) | C$ (23,500) | 14.0% |
| Net Loss from Continuing Operations | C$ (262,900) | C$ (515,500) | 49.0% |
| Free Cash Flow | C$ (69,100) | C$ (176,600) | 60.9% |
Sources: [1, 4, 17, 20]
Figures in Millions of Canadian Dollars (CAD)
| Fiscal Year | Total Net Revenue | Annual Change (%) | Canadian Medical Share (%) | Storz & Bickel Share (%) |
|---|---|---|---|---|
| FY2021 | C$ 546.7 | 38.0% | 11.2% | 15.6% |
| FY2022 | C$ 520.3 | (4.8)% | 11.8% | 16.2% |
| FY2023 | C$ 402.9 | (22.6)% | 15.2% | 18.4% |
| FY2024 | C$ 297.1 | (26.3)% | 20.6% | 22.0% |
| FY2025 (Restated) | C$ 268.6 | (9.6)% | 28.7% | 26.3% |
| FY2026 | C$ 284.6 | 6.0% | 31.9% | 24.8% |
| FY2027 (Estimate) | C$ 348.0 | 22.3% | 34.0% | 23.0% |
Sources: [1, 8, 21, 22, 23, 24]
The key balance sheet change in fiscal 2026 was a capital restructuring that eliminated going-concern risk.[5] By converting debt into equity and raising capital through its At-The-Market (ATM) equity programs, the company ended the year with C$364.7 million in cash and cash equivalents.[1] Total debt was reduced to C$234.0 million, resulting in a net cash position of C$131.3 million.[4, 12]
To secure additional liquidity, the company entered into a senior secured term loan in late fiscal 2026 with a principal amount of US$162.1 million (with cash proceeds of US$150.0 million).[7] This loan is priced at Term SOFR plus 6.25%, with a 3.25% SOFR floor, and includes make-whole provisions.[7] While this loan provides financial flexibility, it adds leverage to the company's capital structure and introduces high interest expenses.[7]
The balance sheet recapitalization came at the expense of significant equity dilution.[25] During fiscal 2026, the company issued 127.5 million common shares under its February 2025 ATM program, raising C$238.4 million, and an additional 56.2 million shares under its August 2025 ATM program, raising C$135.8 million.[7] Furthermore, the acquisition of MTL Cannabis was funded through the issuance of 41.2 million common shares alongside C$18.5 million in cash.[7] These transactions increased the company’s common share count to 422.15 million by June 2026, diluting existing shareholders and limiting per-share equity upside.[7]
Canopy Growth trades at a forward Price-to-Sales (P/S) ratio of 1.3x to 1.4x, which aligns with peer averages in the Canadian licensed producer sector.[21, 26] The company trades at a Price-to-Book (P/B) ratio of approximately 0.73x to 0.82x, indicating that the market is discounting its tangible assets due to ongoing operational losses.[27, 28] Enterprise value metrics, such as EV-to-EBITDA, are not currently meaningful given the company's negative EBITDA.[27, 29] While the net cash position of C$131.3 million provides some downside protection, the stock's valuation remains speculative until the company can demonstrate a sustainable path to GAAP net income.[1, 3]
Investing in Canopy Growth involves navigating significant operational, regulatory, and corporate governance risks.
The primary near-term risk is the financial restatement announced in mid-2026.[6, 7] During the audit process for fiscal 2026, management identified a technical non-cash accounting error regarding share-settled warrants denominated in U.S. dollars.[6] Under accounting guidelines, these warrants should have been classified as liabilities rather than equity because of the company's Canadian dollar functional currency, requiring ongoing fair value adjustments.[6, 7]
As a result, the audit committee concluded that previously issued financial statements for fiscal 2024, fiscal 2025, and several quarterly periods should no longer be relied upon.[6, 7] This error led to a determination that internal controls over financial reporting were ineffective as of March 31, 2026.[7] This governance lapse is reflected in the company's ISS QualityScore of 6, marked by a high-risk Audit sub-score of 10.[30] Remediation efforts will require significant administrative resources and costs, and any failure to resolve these weaknesses could result in delayed filings, regulatory scrutiny, or listing challenges on the TSX and Nasdaq.[7]
Additionally, executive compensation has risen despite ongoing GAAP losses, creating potential misalignment with shareholders.[25] For fiscal 2025, CEO Luc Mongeau's total compensation package was valued at CA$2.00 million, while CFO Thomas Stewart’s compensation was CA$2.70 million.[25] This compensation occurred alongside a consolidated net loss of C$262.9 million.[1, 25] Insiders also executed several stock sales in early 2026, including transactions by board chair David Lazzarato and directors Joseph Bayern, Margaret Atkins, and Theresa Yanofsky, which may weigh on investor sentiment.[29]
Although Germany represents a strong international growth market, it faces severe price compression.[10, 16] The rapid expansion of medical cannabis licenses and imports has led to significant competition.[16] Between early 2025 and mid-2026, the number of tracked medical flower lines in German pharmacies rose from 724 to over 1,800, which contributed to a near 33% decline in the average price per gram.[16] If Canopy Growth cannot maintain premium margins for its Tweed brand, its European medical segment may face lower margins despite higher sales volumes.[8, 15, 16]
The U.S. regulatory environment remains uncertain. While the DEA’s proposal to reschedule cannabis to Schedule III would eliminate Section 280E tax burdens for state-legal businesses, implementation faces legal challenges and administrative delays.[26] Furthermore, because major stock exchanges prohibit the listing of companies with direct U.S. plant-touching operations, Canopy Growth cannot consolidate the revenues or cash flows of Canopy USA, LLC on its primary balance sheet.[9, 18] This structure leaves Canopy’s U.S. assets as an unconsolidated equity option, which may limit the valuation upside for public market investors until listing rules are formally modified.[9]
Canopy’s Canadian medical cannabis segment is highly dependent on medical reimbursement policies funded by Veterans Affairs Canada (VAC).[12] VAC covers medical cannabis costs for a significant portion of Canopy's high-volume medical patients.[9, 12] Any administrative changes, cost-containment measures, or caps on reimbursement rates introduced by the Canadian government would represent a direct headwind for the company's highest-margin segment.[9, 12]
To model Canopy Growth’s long-term performance, this scenario analysis outlines three distinct operational paths from fiscal 2027 through fiscal 2031, reflecting varying integration, regulatory, and pricing outcomes.
| Variable | Bull Case Scenario | Base Case Scenario | Bear Case Scenario |
|---|---|---|---|
| Net Revenue CAGR | 16.0% – 20.0% | 6.0% – 8.0% | (5.0)% – (2.0)% |
| Adjusted EBITDA Margin | Positive by Q2 FY2027; scaling to 15% by FY2031 | Positive by Q4 FY2027; scaling to 6% by FY2031 | Fails to reach breakeven; persistent cash burn |
| Remediation of Controls | Completed in H1 FY2027 with clean audit reviews | Completed in H2 FY2027; minor administrative costs | Fails to remediate; delayed filings and Nasdaq warnings |
| Germany Medical Dynamic | Captures 12% premium import share; stable margins | Captures 7% import share; faces price compression | Share falls to <4% due to low-cost competitors |
| Canopy USA Structure | Full consolidation by FY2029 post-listing reform | Unconsolidated; remains an off-balance-sheet option | Dissolved or restructured due to legal challenges |
| Free Cash Flow Status | Sustained positive FCF starting in FY2028 | Approaching FCF breakeven by FY2029 | Persistent cash burn; reliance on dilutive ATM raises |
| 12-Month Target Price | USD $2.25 (C$3.15) | USD $1.25 (C$1.75) | USD $0.50 (C$0.70) |
Sources: Analytical Projections based on [1, 3, 9, 12, 16, 31, 32, 33, 34]
Under the Bull Case, Canopy Growth successfully integrates the MTL Cannabis acquisition, achieving the full C$10.0 million in annualized cost synergies by early fiscal 2027.[3, 12] The availability of premium medical flower allows the company to defend its leading medical position in Canada and capture market share in Germany.[2, 15] This helps mitigate German price compression, while the company maintains premium pricing under its Tweed and Spectrum Therapeutics brands.[15, 16]
In the United States, the DEA completes its Schedule III rescheduling process, triggering stock exchange reforms that allow plant-touching businesses to list on major exchanges.[9, 26] This enables Canopy Growth to consolidate the financial results of Canopy USA, LLC by fiscal 2029, driving significant revenue and EBITDA growth.[18, 19] The audit committee quickly resolves the material weaknesses in internal controls with minimal administrative disruption, restoring institutional investor confidence.[7] Free cash flow turns positive by fiscal 2028, and the 12-month target price increases to USD $2.25.[1, 32]
The Base Case assumes Canopy Growth achieves its goal of positive Adjusted EBITDA during fiscal 2027, supported by ongoing G&A savings and the partial realization of MTL Cannabis synergies.[3, 12] Canadian adult-use market share stabilizes, but competitive pressures restrict Q4 growth to low single digits.[1, 12] In Germany, higher export volumes are offset by ongoing price-per-gram compression, resulting in flat international margins.[8, 16]
U.S. rescheduling to Schedule III is completed, but major stock exchanges maintain listing restrictions for plant-touching operators.[9, 26] As a result, Canopy USA remains an unconsolidated vehicle, acting as an off-balance-sheet equity option.[9, 18] Internal control weaknesses are resolved by the end of fiscal 2027, though this requires higher administrative spending.[7] Free cash flow approaches breakeven by fiscal 2029, and the 12-month target price remains near the analyst consensus of USD $1.25.[32, 35]
In the Bear Case, Canopy Growth faces operational challenges and market pressures. The Canadian medical cannabis segment is impacted by potential VAC reimbursement cuts, leading to a decline in medical revenues.[9, 12] In Germany, aggressive price competition from low-cost European and Canadian exporters reduces average prices, causing international margins to contract.[8, 16] Storz & Bickel vaporizer sales continue to decline, and the division requires further brand and goodwill write-downs.[8, 17]
Additionally, the company struggles to remediate its material weaknesses in internal controls, resulting in delayed filings and regulatory warnings from Nasdaq.[7] This forces the company to rely heavily on its highly dilutive ATM programs to meet short-term debt obligations, such as payments on its US$162.1 million senior secured term loan.[7] Severe equity dilution pushes the share price down, leading to a 12-month target price of USD $0.50.[32]
To evaluate Canopy Growth's competitive position, this scorecard compares the company against its closest Canadian licensed producer peers—Tilray Brands (TLRY), Aurora Cannabis (ACB), and Cronos Group (CRON)—across key operational metrics.
| Valuation and Operating Metric | Canopy Growth (CGC) | Tilray Brands (TLRY) | Aurora Cannabis (ACB) | Cronos Group (CRON) |
|---|---|---|---|---|
| Market Cap (USD) | $ 425.84 M | $ 1.95 B | $ 345.00 M | $ 850.00 M |
| Net Cash / (Debt) Position | C$ 131.30 M | C$ (180.00) M | C$ 25.00 M | C$ 820.00 M |
| U.S. Option Structure | Off-Balance Sheet (Strong) | Craft Beer / Non-THC (Neutral) | None (Weak) | Equity Option (Neutral) |
| German Import Capability | Strong (EU-GMP & Tweed) | Strong (Local Cultivation) | Strong (Medical Focus) | Moderate (Spinach Brand) |
| EBITDA Profitability Path | FY27 Target (Neutral) | Breakeven (Neutral) | Positive (Strong) | Breakeven (Neutral) |
| Financial Controls Status | Material Weakness (Weak) | Effective (Strong) | Effective (Strong) | Effective (Strong) |
| Overall Analyst Recommendation | Hold / Neutral | Hold / Neutral | Hold / Neutral | Hold / Neutral |
Sources: [1, 3, 7, 10, 12, 21, 26, 27, 28, 30, 31]
Canopy Growth’s recapitalization improved its liquidity, shifting the company to a net cash position of C$131.3 million.[1, 4] However, it remains behind Cronos Group, which holds over C$800 million in debt-free cash reserves. While Tilray Brands faces debt obligations, its diversified cash flows from its U.S. craft beer portfolio provide some buffer.[5] Canopy Growth continues to experience cash outflows, with a free cash outflow of C$69.1 million in fiscal 2026, meaning its liquidity remains exposed to ongoing operational burn.[1]
Canopy Growth has a competitive advantage in its U.S. expansion strategy through the Canopy USA structure.[18, 19] By utilizing an off-balance-sheet vehicle, Canopy can execute acquisitions of premium U.S. brands like Wana and Jetty without jeopardizing its Nasdaq listing.[9, 18] Aurora Cannabis has focused primarily on international medical markets, leaving it with minimal U.S. consumer exposure. Tilray has built a craft beverage footprint, but lacks direct plant-touching assets in the United States, which may limit its near-term growth if federal regulations ease.[18, 19]
Aurora Cannabis has executed an efficient overhead rationalization program, achieving consistent Adjusted EBITDA profitability ahead of its peers. In comparison, Canopy Growth is still in the execution phase of its cost-reduction plans.[3, 12] While Canopy reduced G&A expenses by 15% and has realized C$6.0 million in synergies from the MTL Cannabis acquisition, it remains unprofitable on a consolidated GAAP basis.[3, 12]
Canopy Growth maintains a strong product portfolio.[2] Tweed’s relaunch in the Canadian adult-use market, combined with premium brand rollouts like "Deelish" and Claybourne’s "Frosted Flyers," has successfully stabilized its market share.[2, 12, 13] Despite current headwinds at Storz & Bickel, the division owns highly regarded vaporizer hardware brands, providing a solid platform for future growth.[3, 8]
Corporate governance is a key differentiator among peers. While Tilray, Aurora, and Cronos maintain clean financial reporting and effective internal controls, Canopy Growth’s historical restatements and ineffective financial controls present ongoing administrative risks.[7] The company's warrant-related restatement is a notable corporate governance hurdle for institutional investors.[6, 7]
Canopy Growth's performance in fiscal 2026 shows a balance between operational progress and persistent financial challenges.[1] Management has successfully executed a major capital recapitalization, converting debt to equity and establishing a net cash position of C$131.3 million, which has resolved previous going-concern risk.[1, 4, 5]
Operationally, the focus on high-margin medical cannabis markets is producing positive results.[11] The acquisition of MTL Cannabis has made Canopy the leading medical cannabis provider in Canada by revenue [2], while Germany's regulatory changes under CanG have driven strong medical sales volumes.[1, 10]
However, these positive trends are offset by corporate governance risks and operational headwinds in other divisions.[7, 8] The restatement of fiscal 2024 and fiscal 2025 financial statements due to warrant accounting errors indicates that internal controls over financial reporting remain ineffective.[6, 7] Furthermore, the Storz & Bickel segment is experiencing declining sales, and the company took a significant goodwill impairment charge of C$67.1 million.[8] In addition, the off-balance-sheet nature of Canopy USA means its assets cannot be consolidated onto the primary income statement, limiting its immediate impact on public valuation.[9, 18]
Given these dynamics, a neutral Hold rating is maintained on Canopy Growth Corporation. The company’s improved balance sheet and strong position in core medical import markets are encouraging, but investors should wait for the company to fully resolve its internal control issues, complete the integration of MTL Cannabis, and achieve positive Adjusted EBITDA in fiscal 2027 before adjusting positions.[3, 7, 12]
As of June 15, 2026, Canopy Growth’s U.S. shares (CGC) are trading at USD $1.03, up 3.50% following the morning earnings call.[15] This price level remains near the lower end of its 52-week trading range of USD $0.84 to $2.38.[15, 27] On the Toronto Stock Exchange, the shares (WEED.CA) closed at C$1.41, representing a marginal 0.70% decline and trading near the lower boundary of a long-term horizontal range between support at C$1.21 and resistance at C$2.62.[27, 36]
The technical profile is highly bearish across multiple timeframes, with the stock currently trading below all of its key short-, medium-, and long-term moving averages.[37, 38]
| Indicator / Moving Average | Pricing Value | Market Trend Signal |
|---|---|---|
| 5-Day Moving Average | USD $1.0180 | Bearish / Sell |
| 20-Day Moving Average | USD $1.0431 | Bearish / Sell |
| 50-Day Moving Average | USD $1.0863 | Bearish / Sell |
| 100-Day Moving Average | USD $1.0814 | Bearish / Sell |
| 200-Day Moving Average | USD $1.1994 | Bearish / Sell |
| Relative Strength Index (RSI-14) | 37.7 – 41.5 | Bearish Momentum / Neutral |
| MACD (12, 26) | (0.005) | Bearish Crossover / Sell |
Sources: [37, 39, 40, 41, 42]
The stock is trading near its psychological support level of USD $1.00.[27, 43] A breakdown below this level would likely test key historical support around USD $0.84 to $0.86, which is aligned with the stock's 52-week low.[27, 31, 39] Conversely, for the stock to establish a sustainable upward trend, it must break through immediate resistance at the 50-day moving average (USD $1.09) and establish support above the 200-day moving average at USD $1.20.[38, 41]
Momentum indicators support this cautious outlook. The MACD has entered negative territory, and the Aroon Indicator suggests a downward trend.[42] However, the Relative Strength Index (RSI) is hovering near oversold territory.[39, 40] Historically, when the stock has remained in this oversold zone for an extended period, it has often experienced short-term, technical rebounds.[42]
This high volatility is reflected in the options market. Implied volatility (IV) is highly elevated, ranging from 112% to 144% depending on expiration dates.[27, 43] The options chain is pricing in a short-term expected price move of roughly 11% [27], with open interest heavily concentrated in near-the-money call and put options at the USD $1.00 strike price.[43]
Given these technical factors, the short-term outlook remains highly speculative. The stock is likely to trade within its current range of USD $0.90 to $1.15 in the near term.[27, 41] Any sustainable upward breakout will depend on the company's ability to demonstrate progress toward its fiscal 2027 Adjusted EBITDA goals and successfully resolve its financial restatements.[3, 7, 12]
View Canopy Growth Corporation (CGC) stock page
Loading the interactive version of this report…